Read our latest news, and find more about us and our portfolio companies.

ALCAN, a German Smart Antenna Start-up, Raises EUR 7.5 million to Manufacture Flat Panel Phased Array Antennas

A consortium of leading global corporations has invested in ALCAN’s market-leading smart antenna technology to support the roll-out of the company’s first flat panel phased array antennas.

Storm Therapeutics expands collaboration with Evotec on Storm's RNA Epigenetics Platform

**STORM Therapeutics and Evotec to exploit RNA modulating enzymes for novel epigenetic drug discovery**

Parkinson’s disease: Prexton announces initiation of phase II clinical testing

Study will evaluate first-in class treatment in six European countries

ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting

- Phase 2 nolasiban previously reported data supports potential for meaningfully increasing live birth rates in ART - Non-clinical results of OBE022 for PTL demonstrate both monotherapy/combination potential

Merck Ventures Creates New Immuno-Oncology Company iOnctura

Darmstadt, Germany, June 20, 2017 – Merck, a leading science and technology company, today announced its corporate venture arm Merck Ventures created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Merck and three assets from Cancer Research Technology (CRT). CRT is the commercial arm of Cancer Research UK, London, UK. Merck Ventures will manage the investment and will be represented on iOnctura’s board of directors.

Artios announces formation of world-leading Scientific Advisory Board

Cambridge, UK, 8 June 2017. Artios Pharma Ltd., a leading DNA Damage Response (DDR) company focussed on developing innovative new treatments for cancer, today announces the formation of its Scientific Advisory Board (SAB) comprised of world-leading experts from across Europe and the United States, in the fields of DDR, DNA genetics and drug discovery. Dr Simon Boulton, VP Scientific Strategy at Artios, will serve as Chairman.

Synaffix Secures End-to-End Patent Protection of Its ADC Technology Platform as Its HydraSpace™ Patent Grants in the United States

exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced that a key patent covering its HydraSpace™ spacer technology has been granted by the United States Patent and Trademark Office (US 9,636,421 B2).

ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Call on Thursday, May 18, 2017

Geneva, Switzerland and Boston, MA - May 11, 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that it will report financial results for the first quarter ended March 31, 2017 on Thursday, May 18, 2017.

VAXIMM Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of VXM01 with Avelumab in Glioblastoma and Colorectal Cancer in Phase I/II Clinical Studies

Basel (Switzerland) and Mannheim (Germany), May 9, 2017 – VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company which in the US and Canada operates as EMD Serono, and Pfizer Inc. (NYSE: PFE) to evaluate avelumab*, a human anti-PD-L1 antibody, in combination with VAXIMM’s VXM01. VXM01 is an investigational oral T-cell immunotherapy designed to activate T-cells to attack the tumor vasculature, and, in several tumor types, attack cancer cells directly. Under the terms of the agreement, VAXIMM will be responsible for conducting two open-label Phase I/II trials – one in glioblastoma and one in metastatic colorectal cancer.

Merck KGaA spinoff licenses IBD drug to Eisai joint venture

Merck KGaA spinoff Calypso Biotech has licensed its inflammatory bowel disease candidate to EA Pharma, a joint venture between Eisai and Ajinomoto. The agreement gives EA Pharma the global license to anti-MMP-9 monoclonal antibody CALY-001.

VAXIMM to present preclinical data on three novel oral T-cell immunotherapies at AACR Annual Meeting 2017

Basel (Switzerland) and Mannheim (Germany), March 30, 2017 - VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that preclinical data for three of its programs will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017 being held in Washington, DC, USA, April 1-5.

Calypso Biotech licenses CALY-001 best-in-class anti-MMP-9 antibody to EA Pharma

Calypso Biotech SA announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody.

ObsEva SA to Attend Needham Annual Healthcare Conference in NYC

ObsEva SA to Attend Needham Annual Healthcare Conference in NYC

Pogue's quest for the best pill-reminder app

I’ll admit it: Apps that remind you to take your pills are not as sexy as, say, folding laptops or MP3 toothbrushes. But they’re important. Every year an estimated 125,000 Americans die from taking their pills incorrectly, according to a 2012 study from the Annals of Internal Medicine.

ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor

- OBE022 is ObsEva's potential first-in-class, oral and selective PGF2alpha receptor antagonist -

ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART

- IMPLANT2 study to confirm efficacy and safety of novel, oral oxytocin receptor antagonist in infertile patients undergoing embryo transfer as part of assisted reproductive technology (ART) -

Medisafe Raises $14.5M in Funding to Support Rapid Growth and Global Expansion

LONDON and BOSTON, March 1, 2017 — Medisafe®, the leading personalized medication management platform with over three and a half million patient and caregiver registered users, announced today that it has raised a $14.5M Series B funding round led by Octopus Ventures, and joined by M Ventures, to support the company’s rapid growth and global expansion. Other investors participating from previous rounds include Pitango Venture Capital, 7wire ventures, lool Ventures, TriVentures and Qualcomm Ventures.

Storm Therapeutics appoints CEO and Chairman

CAMBRIDGE, UK (24 FEB 2017) - Storm Therapeutics, the drug discovery company focused on the discovery of small molecule therapies from RNA epigenetics, moved to the next stage of its development with the appointment of Keith Blundy as Chief Executive Officer and Tim Edwards as Chairman.

New Data Demonstrate Significant Expansion of Therapeutic Index vs Cysteine-Engineered ADCs

AMSTERDAM, NETHERLANDS – February 20, 2017 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced a new set of head-to-head data, that demonstrates the potential of its technology to significantly expand the therapeutic index vs cysteine-engineered ADCs.

Prexton Therapeutics Series B financing round raises €29 million ($31M) to advance its novel Parkinson’s therapeutic

**Forbion & Seroba co-led funding, forming international consortium of Merck Ventures, Ysios and Sunstone Funding to finance two Phase II trials in Parkinson’s disease** **Geneva, Switzerland and Amsterdam, The Netherlands, February 7, 2017** - Prexton Therapeutics (Prexton), a biopharmaceutical company developing novel therapeutic compounds for the treatment of Central Nervous System (CNS) conditions, today announces the closing of a Series B financing round of €29 million ($31M).

ObsEva SA Announces Pricing of Initial Public Offering

Geneva, Switzerland - January 25, 2017 - ObsEva SA (ObsEva) announced today the pricing of its initial public offering of 6,450,000 common shares at the initial public offering price of $15.00 per share. In addition, ObsEva has granted the underwriters an option to purchase up to 967,500 additional common shares to cover over-allotments. The offering is expected to close on or about January 31, 2017, subject to customary closing conditions. ObsEva's common shares have been approved for listing on The NASDAQ Global Select Market and are expected to begin trading under the ticker symbol "OBSV" on January 26, 2017. Credit Suisse Securities (USA) LLC, Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the proposed offering.

ARTSaVIT Ltd. Completes $6.3 Million Series A Financing

YAVNE, Israel, January 5, 2016 - Israeli cancer apoptosis company ARTSaVIT LTD announced today that it has completed a $6.3 million Series A round of financing led by Arkin Bio Ventures and Pontifax, with participation of Merck Ventures, Carmel Innovation and Carmel - Haifa University Economic Corporation Ltd.